Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Beginning Cash Balance (2018 - 2023)

Endonovo Therapeutics has reported Beginning Cash Balance over the past 6 years, most recently at $4500.0 for Q2 2023.

  • Quarterly results put Beginning Cash Balance at $4500.0 for Q2 2023, up 28.57% from a year ago — trailing twelve months through Sep 2023 was $12000.0 (down 25.0% YoY), and the annual figure for FY2022 was $14000.0, down 17.16%.
  • Beginning Cash Balance for Q2 2023 was $4500.0 at Endonovo Therapeutics, up from $3000.0 in the prior quarter.
  • Over the last five years, Beginning Cash Balance for ENDV hit a ceiling of $35000.0 in Q3 2019 and a floor of -$11600.0 in Q3 2021.
  • Median Beginning Cash Balance over the past 5 years was $4750.0 (2020), compared with a mean of $7837.5.
  • Peak annual rise in Beginning Cash Balance hit 230.0% in 2021, while the deepest fall reached 293.33% in 2021.
  • Endonovo Therapeutics' Beginning Cash Balance stood at $30000.0 in 2019, then plummeted by 90.0% to $3000.0 in 2020, then surged by 116.67% to $6500.0 in 2021, then crashed by 30.77% to $4500.0 in 2022, then changed by 0.0% to $4500.0 in 2023.
  • The last three reported values for Beginning Cash Balance were $4500.0 (Q2 2023), $3000.0 (Q1 2023), and $4500.0 (Q4 2022) per Business Quant data.